Lexicon Pharmaceuticals | LXRX - Bienes





Bienes Cambio Fecha
Abbott USD 86.71B 2.53B 2025-12
Acadia Pharmaceuticals USD 1.56B 233.42M 2025-12
Agios Pharmaceuticals USD 1.3B 88.48M 2025-12
Akebia Therapeutics USD 376.56M 12.41M 2025-12
Alnylam Pharmaceuticals USD 4.97B 114.67M 2025-12
AstraZeneca USD 114.07B 382M 2025-12
BioMarin Pharmaceutical USD 7.59B 20.85M 2025-12
Coherus Biosciences USD 258.34M 258.18M 2025-12
Eli Lilly USD 112.48B 2.46B 2025-12
Esperion Therapeutics USD 465.89M 101.87M 2025-12
Halozyme Therapeutics USD 2.53B 304.09M 2025-12
Illumina USD 6.64B 467M 2025-12
Insmed USD 2.26B 96.18M 2025-12
Ironwood Pharmaceuticals USD 396.06M 53.12M 2025-09
J&J USD 199.21B 6.39B 2025-12
Lexicon Pharmaceuticals USD 184.99M 20.94M 2025-12
MacroGenics USD 256.85M 13.92M 2025-12
MannKind USD 792.18M 297.54M 2025-12
Merck USD 129.55B 12.02B 2025-09
Moderna USD 12.34B 203M 2025-12
Novartis USD 110.95B 3.66B 2025-12
PTC Therapeutics USD 2.9B 255.07M 2025-12
Puma Biotechnology USD 202.86M 7.95M 2025-09
Sarepta Therapeutics USD 3.35B 143.73M 2025-12
Thermo Fisher Scientific USD 110.34B 7.32B 2025-12
Ultragenyx Pharmaceutical USD 1.53B 341.56M 2025-12
United Therapeutics USD 7.88B 528.9M 2025-12
Vanda Pharmaceuticals USD 488.95M 112.19M 2025-12